Ibandronate
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postmenopausal Osteoporosis
Conditions
Postmenopausal Osteoporosis
Trial Timeline
Jun 1, 2004 → Apr 1, 2006
NCT ID
NCT02604836About Ibandronate
Ibandronate is a approved stage product being developed by Roche for Postmenopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02604836. Target conditions include Postmenopausal Osteoporosis.
What happened to similar drugs?
6 of 20 similar drugs in Postmenopausal Osteoporosis were approved
Approved (6) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02561039 | Phase 3 | Completed |
| NCT00545779 | Phase 3 | Completed |
| NCT02553707 | Approved | Completed |
| NCT00545363 | Approved | Completed |
| NCT02716792 | Phase 3 | Completed |
| NCT02598453 | Approved | Completed |
| NCT02564107 | Approved | Completed |
| NCT02598934 | Approved | Completed |
| NCT02604836 | Approved | Completed |
Competing Products
20 competing products in Postmenopausal Osteoporosis